Regulatory23 May 2026, 05:00 pm
Sai Parenterals: No Deviation in IPO Funds Utilization
AI Summary
Sai Parenterals Ltd reports no deviations or variations in the utilization of proceeds from its Initial Public Offer (IPO) for the quarter and year ended March 31, 2026. This is in compliance with Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The IPO raised ₹2,850 million, and the funds were allocated to various objectives, including capacity expansion, R&D, debt repayment, working capital, and general corporate purposes. Monitoring agency M/s. India Ratings & Research Private Limited confirmed no deviations.
Key Highlights
- Sai Parenterals confirms no deviation in IPO fund utilization for the period ending March 31, 2026.
- IPO proceeds of ₹2,850 million were allocated as planned across multiple objectives.
- Compliance with SEBI regulations regarding deviation or variation of funds.
- Monitoring agency, M/s. India Ratings & Research Private Limited, found no deviations.
Price Impact
More from SAIPARENT